Oramed Pharmaceuticals (NASDAQ:ORMP) reported quarterly losses of $(0.18) per share. This is a 5.88 percent decrease over losses of $(0.17) per share from the same period last year.
Morgan Stanley Maintains Overweight on Iridium Comms, Raises Price Target to $50
Morgan Stanley analyst Landon Park maintains Iridium Comms (NASDAQ:IRDM) with a Overweight and raises the price target from $49 to $50.
